What is InNexus Biotechnology, Inc. (IXSBF) stock price today?

InNexus Biotechnology, Inc. (IXSBF) is currently trading at $0.00.

What is IXSBF return on equity (ROE)?

InNexus Biotechnology, Inc.'s return on equity (ROE) is 140.00%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is InNexus Biotechnology, Inc.'s market cap?

InNexus Biotechnology, Inc. has a market capitalization of $12627.

OTC · Medical - Pharmaceuticals

InNexus Biotechnology, Inc. (IXSBF) Stock

$0.00 OTC: IXSBF Healthcare

InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies.

Valuation

Metric	Value
Price	$0.00
Market Cap	$12627
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	0.00
EPS (TTM)	$-0.07
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	140.00%
ROA	-233.33%
ROCE	76.64%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.60
Current Ratio	0.00

Annual Financials (USD)

Metric	2005	2006	2007	2008	2009
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-3.0M	$-5.0M	$-6.0M	$-7.0M	$-4.0M
Net Profit	$-3.0M	$-5.0M	$-6.0M	$-8.0M	$-7.0M
EPS	$-0.12	$-0.13	$-0.11	$-0.11	$-0.07
Op Margin	-5758.2%	-33603.6%	-565567.3%	—	—

Balance Sheet (USD)

Metric	2005	2006	2007	2008	2009
Total Assets	$1.0M	$7.0M	$6.0M	$5.0M	$3.0M
Total Liabilities	$0	$2.0M	$2.0M	$7.0M	$9.0M
Cash	$1.0M	$3.0M	$3.0M	$0	$0
Borrowings	$0	$0	$0	$3.0M	$3.0M

Latest News

Strathcona Resources Ltd. Reports Second Quarter 2026 Financial and Operating Results and Announces Quarterly Dividend CNW Group · Aug 5, 2026 Disney Reaffirms Double-Digit Earnings Growth, Targets $9 Billion in Buybacks. Here’s What Investors Need to Know. Motley Fool · Aug 5, 2026 Meta Platforms Launches Muse Code AI Coding Tool Powered by Muse Spark 1.2 MT Newswires · Aug 5, 2026 Dow Jones Futures: Nvidia Lifts Dow, But Google, SpaceX Skid; Sandisk, Western Digital Lead Earnings Losers Late Investor's Business Daily · Aug 5, 2026 A Life360 Director Sold Stock at Exactly $60. Here's What Long-Term Investors Should Know Motley Fool · Aug 5, 2026

Cash Flow (USD)

Metric	2005	2006	2007	2008	2009
Operating Cash Flow	$-2.0M	$-2.0M	$-8.0M	$-3.0M	$-2.0M
Investing Cash Flow	$-1.0M	$-4.0M	$3.0M	$-2.0M	$0
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$1.0M	$2.0M	$0	$-3.0M	$0
Free Cash Flow	$-3.0M	$-3.0M	$-10.0M	$-3.0M	$-2.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-1.15
FCF Yield	-9041.78%
Quick Ratio	0.00
Interest Coverage	-1.41
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BMGPBiomagnetics Diagnostics Corp.	$0.00	—	0.00	$1265	0.00%
NNLXNanoLogix, Inc.	$0.00	—	-0.01	$9569	0.00%
ORHBORHub, Inc.	$0.00	—	-0.01	$27500	0.00%
OZYMFStrategic Partners A/S	$90.00	+0.00%	-36.17	$3.72M	0.00%
PXMDPaxMedica, Inc. Common Stock	$0.00	—	0.00	$88385	0.00%

About InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.

InNexus Biotechnology, Inc. (IXSBF) stock trades at $0.00 with a market capitalization of $12627. The stock is valued at price-to-book of 0.00, price-to-sales of 0.00.

On profitability, InNexus Biotechnology, Inc. generates a return on equity (ROE) of 140.00% (not meaningful, as shareholders' equity is negative), return on capital employed of 76.64%.

Official website: www.innexusbiotech.com/